Eyenuk vs VUNO

VUNO sells a wide range of products from Seoul: Med-Chest X-ray, Med-DeepBrain, Med-BoneAge, Med-Fundus AI for retinal photographs and Med-DeepCARS for cardiac arrest risk. The FDA-cleared parts suit a hospital radiology department, namely DeepBrain for brain MR volumetry (K231398, October 4, 2023) and chest X-ray triage for adult pleural effusion and pneumothorax (K241439, November 15, 2024). Eyenuk sells EyeArt to clinics and screening programs.

The two overlap in retinal screening, and there VUNO is the weaker pick for a US primary care group buying a diabetic eye screen, since openFDA lists no decision under the name Vuno for Med-Fundus AI while EyeArt holds K200667 and K223357 under product code PIB. Outside the US the approvals differ. VUNO's history page records MFDS Class III approval for Med-Fundus AI in April 2020, and Eyenuk claims a Class IIb CE mark under the EU MDR for diabetic retinopathy, AMD and glaucoma.